[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"constipation-predominant-irritable-bowel-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:constipation-predominant-irritable-bowel-syndrome":94},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100626155","phase-4-efficacy-and-safety-of-linaclotide-in-chronic-constipation-100626155",false,"NCT07431957","\"Efficacy and Safety of Linaclotide in Chronic Constipation\"","\"Efficacy and Safety of Linaclotide in Chronic Constipation : A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study\"","LIN-CC-BD","Inclusion Criteria:\n\n* Adult patients (18-70 years)\n* patients diagnosed with CIC or IBS-C based on Rome IV criteria\n* No abnormal finding on colonoscopy conducted within past 1 year\n* Patients who can read and are willing to complete daily bowel diary and follow study procedures\n\nExclusion Criteria:\n\n* Clinical features suggestive of organic disease ( Anaemia, unexplained weight loss, per rectal bleeding, family history of malignancy)\n* Secondary constipation due to structural, metabolic, or neurological causes (IBD, Colorectal cancer, hypothyroidism, hypercalcemia, DM, Parkinson's disease)\n* History of or new onset intestinal obstruction\n* Prior history of stomach, small intestine and colorectal surgery ( except appendectomy or hemorroidectomy)\n* Patients currently suffering from medication induced costipation ( opioids, anti choline raids, calcium channel blockers, oral iron and calcium supplements, anti-Parkinsonian drug, antipsychotic, anti-emetics or psychostimulant drugs)\n* Use of medication affecting bowel motility ( Lubiprostone, Elobixibat, PEG or prosecretory agents) within 2 week before enrollment\n* Serious cardiovascular, respiratory, renal, GI, hepatic, hematological, neurological or psychiatric illness\n* Pregnancy or lactation","ALL","18 Years","70 Years",{"count":21,"type":22},90,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Goal of this study is to evaluate the efficacy and safety of two different doses of Linaclotide in improving bowel function and patient-reported outcomes among Bangladeshi patients with chronic constipation for 8 weeks along with an additional short drug-free follow up period of 2 weeks. The main question it aims to answer is \"Does Linaclotide at doses of 72microgram or 145microgram once daily improve bowel function and patient-reported coutcomes compared with placebo in Bangladeshi patients with chronic constipation over an 8-week treatment period?\"\n\nStudy procedure:\n\nFrom outpatient department of Gastroenterology, Dhaka Medical College, a total of 90 adult patients diagnosed with chronic idiopathic constipation (CIC) or constipation predominant irritable bowel syndrome (IBS-C) by ROME-IV criteria will be selected after baseline evaluation including clinical history, physical examination, laboratory tests and colonoscopy. Before enrollment eligible participants will undergo 1-week baseline stool diary which will include baseline data of patient reported severity of abdominal symptoms (bowel movement, stool frequency, bloating, abdominal pain or discomfort and defecatory satisfaction score). Patients reporting more than 3 SBMs during baseline run in period will be excluded from the study. Finally total 90 patients will be enrolled as participants who will be randomly assigned to one of the three groups, Group A (Linaclotide 72mcg once daily), Group B (Linaclotide 145mcg once daily) and Group C (Placebo once daily ). The treatment period will start from randomization visit (day 0) and will be continued for 8 weeks. All participants will receive identical looking drugs (72mcg or 145mcg or placebo) 30 minutes before breakfast and they will be requested to maintain standard dietary and lifestyle advices including increased intake of high fiber diet and fluid throughout the study. Patients will record spontaneous bowel movement (SBM) and complete spontaneous bowel movement (CSBM), stool consistency using Bristol Stool Form Scale (BSFS), severity of abdominal symptoms by 5-point Likert scale, use of rescue medication after 3 days of absolute constipation and adverse events such as diarrhea in their daily stool diary. They will be followed up at week-4, week-8 and after 2-week drug free withdrawal period at week-10 with review of stool diary and safety assessments. Entire study will be monitored by Data Safety Monitoring Board (DSMB) of Dhaka Medical College.",[28,29,30,31,32],"Chronic Idiopathic Constipation","Irritable Bowel Syndrome (IBS-C)","Chronic Constipation","CIC","Constipation Predominant Irritable Bowel Syndrome",[34,31,35,36,37,38,39,15,40,29],"CC","IBS-C","Chronic Constipation (CC)","Chronic Idiopathic Constipation (CIC)","Constipation predominant Irritable Bowel Syndrome (IBS-C)","Linaclotide","Linaclotide RCT","NOT_YET_RECRUITING","2026-02-21",{"date":44,"type":45},"2026-02-25","ACTUAL",{"date":47,"type":22},"2026-02-20",{"date":49,"type":22},"2027-01-31",{"name":51,"class":52},"Md Mehedi Shahriar","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":80,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":53},"100622820","soluble-and-osmotic-fibre-solos-diet-for-constipation-100622820","NCT07388589","Soluble and Osmotic Fibre (SOLOS) Diet for Constipation","The Soluble and Osmotic Fibre (SOLOS) Diet for Functional Bowel Disorders With Constipation","SOLOS","Inclusion Criteria:\n\n* Presented with symptoms of FC, IBS-C, or SIBO-C\n* Were aged 18 to 70 years old. (Research focus is on adult patients, excluding older adults and children)\n* Date of baseline (first) and follow-up appointments ranged from January 2021 to December 2025\n* Did not attend follow-up appointments (Data would be treated as \"intention to treat\" and data points were carried forward for conservative analysis).\n\nExclusion Criteria:\n\n* Had no history of constipation-related symptoms (Does not relate to research question's population or outcome)\n* Started treatment before January 2021\n* Were not due for follow-up before the end of December 2025\n* Symptom and stool data inadequately recorded",{"count":63,"type":22},180,"OBSERVATIONAL","This research aims to study the dual effectiveness of incorporating soluble fibre and osmotic carbohydrates (SOLOS), with or without restricting fructans and GOS, and present novel findings in managing GI symptoms in patients with functional bowel disorders with constipation. These findings may also support researchers and clinicians in shaping new dietary approaches in the management of general constipation symptoms.",[67,68,69,32,70,71,72,73,74,75,76,77,78,79],"Constipation","Constipation - Functional","Constipation Chronic Idiopathic","Constipation, Signs and Symptoms, Digestive","Constipation-predominant IBS (IBS-C)","Constipation-predominant Irritable Bowel Syndrome","Constipation-predominant Irritable Bowel Syndrome (IBS-C)","Diet Therapy","Diet Modification","Diet, Food and Nutrition","Dietary and Nutritional Therapies","Dietary Fiber","Dietary Fibers",[67,81,82,83,84],"Functional constipation","Constipation-predominant irritable bowel syndrome (IBS-C)","Soluble fiber","osmotic sugar","2026-02-04",{"date":87,"type":45},"2026-02-06",{"date":89,"type":22},"2026-02-02",{"date":91,"type":22},"2027-03-01",{"name":93,"class":52},"Singapore Institute of Technology","Constipation-Predominant Irritable Bowel Syndrome"]